Talis Biomedical Corporation Common Stock
TLIS
TLIS was delisted on the 30th of August, 2024.
35 hedge funds and large institutions have $12.1M invested in Talis Biomedical Corporation Common Stock in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 5 increasing their positions, 17 reducing their positions, and 15 closing their positions.
6.54% less ownership
Funds ownership: 62.56% → 56.02% (-6.5%)
20% less funds holding
Funds holding: 44 → 35 (-9)
40% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 15
49% less capital invested
Capital invested by funds: $23.6M → $12.1M (-$11.5M)
71% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
+$300K |
| 2 |
Millennium Management
New York
|
+$213K |
| 3 |
Renaissance Technologies
New York
|
+$96.1K |
| 4 |
E
Ergoteles
New York
|
+$73.2K |
| 5 |
Mercer Global Advisors
Denver,
Colorado
|
+$72.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$965K |
| 2 |
BlackRock
New York
|
-$757K |
| 3 |
State Street
Boston,
Massachusetts
|
-$212K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$127K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$101K |
TLIS Hedge Fund Activity: Q2 2022 in Review
35 of the 5,960 institutional investors tracked by Wall St. Rank reported a position in Talis Biomedical Corporation Common Stock (TLIS) for Q2 2022, worth a combined $12.1M — down 49% from $23.6M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of TLIS and 9 opened new positions — a net loss of 6 holders — while 17 trimmed existing stakes and 5 added.
The largest buyer was Newtyn Management, opening a new position worth an estimated $300K. The largest seller was ArrowMark Colorado Holdings, cutting an estimated $965K.
- 35 institutional investors held Talis Biomedical Corporation Common Stock (TLIS) as of Q2 2022, down from 44 in Q1 2022.
- Funds reported $12.1M of Talis Biomedical Corporation Common Stock stock for Q2 2022, down 49% quarter-over-quarter.
- 9 funds opened new Talis Biomedical Corporation Common Stock positions in Q2 2022 and 15 closed out, a net change of -6 holders.
- The largest Talis Biomedical Corporation Common Stock buyer in Q2 2022 was Newtyn Management, an estimated $300K added.
- The largest Talis Biomedical Corporation Common Stock seller in Q2 2022 was ArrowMark Colorado Holdings, an estimated $965K sold.
Based on aggregated 13F filings for Q2 2022.